Diversified Trust Co Takes Position in Glaukos Corporation $GKOS

Diversified Trust Co bought a new stake in Glaukos Corporation (NYSE:GKOS) during the second quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor bought 4,205 shares of the medical instruments supplier’s stock, valued at approximately $434,000.

Other institutional investors have also modified their holdings of the company. Wellington Management Group LLP grew its position in shares of Glaukos by 6.1% during the 1st quarter. Wellington Management Group LLP now owns 2,290,790 shares of the medical instruments supplier’s stock valued at $225,460,000 after buying an additional 131,251 shares during the last quarter. Alliancebernstein L.P. grew its position in shares of Glaukos by 56.5% during the 1st quarter. Alliancebernstein L.P. now owns 1,277,539 shares of the medical instruments supplier’s stock valued at $125,735,000 after buying an additional 461,386 shares during the last quarter. Primecap Management Co. CA grew its position in shares of Glaukos by 0.3% during the 1st quarter. Primecap Management Co. CA now owns 1,218,475 shares of the medical instruments supplier’s stock valued at $119,922,000 after buying an additional 4,150 shares during the last quarter. Westfield Capital Management Co. LP grew its position in shares of Glaukos by 34.3% during the 1st quarter. Westfield Capital Management Co. LP now owns 1,084,184 shares of the medical instruments supplier’s stock valued at $106,705,000 after buying an additional 277,033 shares during the last quarter. Finally, Driehaus Capital Management LLC grew its position in shares of Glaukos by 18.7% during the 1st quarter. Driehaus Capital Management LLC now owns 973,625 shares of the medical instruments supplier’s stock valued at $95,824,000 after buying an additional 153,502 shares during the last quarter. Institutional investors and hedge funds own 99.04% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages recently weighed in on GKOS. Zacks Research downgraded shares of Glaukos from a “strong-buy” rating to a “hold” rating in a research report on Friday, August 15th. William Blair raised shares of Glaukos to a “strong-buy” rating in a research report on Thursday, July 31st. BTIG Research reaffirmed a “buy” rating and set a $118.00 price objective on shares of Glaukos in a research report on Wednesday, September 10th. Wells Fargo & Company boosted their price objective on shares of Glaukos from $86.00 to $92.00 and gave the company an “equal weight” rating in a research report on Thursday, July 31st. Finally, Mizuho set a $130.00 price objective on shares of Glaukos in a research report on Thursday, July 31st. One equities research analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $123.58.

Glaukos Stock Up 0.0%

GKOS stock opened at $84.66 on Wednesday. Glaukos Corporation has a 12 month low of $77.10 and a 12 month high of $163.71. The firm has a market cap of $4.86 billion, a PE ratio of -51.31 and a beta of 0.77. The firm has a 50 day simple moving average of $90.71 and a 200 day simple moving average of $94.30. The company has a debt-to-equity ratio of 0.09, a current ratio of 5.51 and a quick ratio of 4.69.

Glaukos (NYSE:GKOS) last released its earnings results on Wednesday, July 30th. The medical instruments supplier reported ($0.24) EPS for the quarter, beating the consensus estimate of ($0.26) by $0.02. Glaukos had a negative net margin of 21.43% and a negative return on equity of 8.59%. The business had revenue of $124.12 million during the quarter, compared to analyst estimates of $115.49 million. During the same period in the prior year, the business earned ($0.52) earnings per share. The business’s quarterly revenue was up 29.7% on a year-over-year basis. Glaukos has set its FY 2025 guidance at EPS. Equities research analysts forecast that Glaukos Corporation will post -1.08 earnings per share for the current fiscal year.

Glaukos Profile

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.